Lexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LEXX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Aug '16 | Aug '17 | Aug '18 | Aug '19 | Aug '20 | Aug '21 | Aug '22 | Aug '23 | Aug '24 | Aug '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
0.09 | 2.53 | 1.74 | 1.35 | 1.31 | 11.75 | 6.16 | 1.48 | 6.56 | 1.97 |
Receivables |
0.13 | 0.05 | 0.27 | 0.27 | 0.31 | 0.34 | 0.20 | 0.13 | 0.15 | 0.37 |
Inventory |
0.13 | 0.07 | 0.09 | 0.13 | 0.12 | 0.03 | 0.04 | — | — | — |
Other current assets |
0.15 | 0.15 | — | — | — | — | — | — | — | — |
Total current assets |
0.51 | 2.80 | 2.28 | 1.82 | 1.93 | 12.44 | 6.98 | 2.15 | 7.90 | 3.47 |
Property, Plant, Equpment (Net) |
0.00 | 0.00 | 0.00 | 0.59 | 0.48 | 0.37 | 0.32 | 0.25 | 0.25 | 0.23 |
Long-term receivables |
— | — | — | — | — | — | — | 0.05 | 0.06 | 0.06 |
Goodwill and Intangible Assets (Total) |
0.05 | 0.06 | 0.15 | 0.27 | 0.29 | 0.36 | 0.49 | 0.46 | 0.52 | 0.31 |
Total non-current assets |
— | — | 0.15 | 0.86 | 0.90 | 0.82 | 0.86 | 0.93 | 0.97 | 0.71 |
Total Assets |
0.57 | — | 2.43 | 2.68 | 2.83 | 13.27 | 7.83 | 3.08 | 8.87 | 4.18 |
Notes Payable |
— | — | 0.01 | 0.05 | 0.06 | 0.01 | — | — | — | — |
Accounts Payable |
0.09 | 0.03 | 0.04 | 0.14 | 0.09 | 0.11 | 0.15 | 0.24 | 1.07 | 1.46 |
Current Part of Debt |
0.33 | 0.04 | 0.01 | — | 0.04 | 0.01 | — | — | — | — |
Current Revenue (Deferred) |
— | — | — | — | 0.04 | — | — | — | 0.01 | 0.00 |
Other current liabilities |
0.01 | 0.02 | — | — | — | — | — | — | — | — |
Total current liabilities |
0.43 | 0.09 | 0.04 | 0.18 | 0.23 | 0.15 | 0.19 | 0.27 | 1.10 | 1.49 |
Long Term Debt (Total) |
0.05 | — | — | — | 0.03 | — | — | — | — | — |
Total non-current liabilities |
— | — | — | — | 0.12 | 0.05 | 0.01 | 0.14 | 0.11 | 0.08 |
Total liabilities |
0.48 | 0.09 | 0.04 | 0.18 | 0.35 | 0.20 | 0.20 | 0.40 | 1.21 | 1.57 |
Additional Paid In Capital |
— | — | 22.10 | 26.17 | 30.32 | 45.09 | 47.04 | 48.80 | 59.60 | 66.50 |
Common Stock (Net) |
0.05 | 0.07 | 0.08 | 0.08 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
Retained Earnings |
(11.30) | (13.17) | (19.77) | (23.87) | (27.80) | (31.83) | (39.10) | (45.76) | (51.56) | (63.46) |
Common Equity (Total) |
0.27 | 3.01 | 2.39 | 2.49 | 2.48 | 13.06 | 7.63 | 2.68 | 7.66 | 2.60 |
Shareholders Equity (Total) |
0.27 | 3.01 | 2.39 | 2.49 | 2.48 | 13.06 | 7.63 | 2.68 | 7.66 | 2.60 |
Shareholders Equity and Liabilities (Total) |
— | — | 2.43 | 2.68 | 2.83 | 13.27 | 7.83 | 3.08 | 8.87 | 4.18 |
Shares (Common) |
— | — | 0.17 | 0.18 | 0.20 | 0.38 | 0.40 | 0.54 | 1.05 | 1.30 |
Shareholders Equity (Tangible) |
— | — | 2.24 | 2.23 | 2.19 | 12.70 | 7.14 | 2.22 | 7.14 | 2.29 |
Net Debt |
0.28 | (2.49) | (1.73) | (1.35) | (1.25) | (11.74) | (6.16) | (1.48) | (6.56) | (1.97) |
Total Debt |
0.38 | 0.04 | 0.01 | — | 0.07 | 0.01 | 0.05 | 0.16 | — | — |